ARDX
ARDELYX, INC.
$5.69
-1.73%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Inst. Holders50 funds
Inst. Value$678.0M
Inst. Activity20 buys / 9 sells
Insider Activity1B / 19S
Insider Net $$538.3K
SEC Reports4
Press Releases2
Recent Activity
Jun 12, 2026
short_volume
Short Volume: ARDX — 55.5% short (0.6M / 1.0M)
Short: 570,533 | Exempt: 1,846 | TRF Vol: 1,027,365 | Short Ratio: 55.5% | Off-exchange volume (dark
May 22, 2026
SEC
Seven ARDX insiders, including CEO and CFO, sold a combined $176K in shares on May 21, 2026, all at the same price of $6
CLUSTER — Impact 2/10
May 22, 2026
SEC
Four C-suite insiders at Ardelyx sold $141K in open-market sales on the same day (May 21, 2026), including the CEO dispo
CLUSTER — Impact 3/10
May 21, 2026
Insider
Kelliher Mike sold 2,900 shares
Chief Business Officer @ $6.27 ($18.2K)
May 21, 2026
Insider
RAAB MICHAEL sold 14,933 shares
President & CEO @ $6.27 ($93.6K)
May 21, 2026
Insider
Williams Laura A sold 1,503 shares
Chief Patient Officer @ $6.27 ($9.4K)
May 19, 2026
SEC
Officer John E. Bishop filed a Form 144 to sell 3,700 shares of Ardelyx common stock (~$23,000) as an automatic sell-to-
144 — Impact 2/10
Inst.
JANUS HENDERSON GROUP PLC — TRIM
8,371,234 shares ($50.1M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$16.33 (Feb 2026)
Current $5.69
Low $13.00
Median $16.00
High $19.00
9 analysts
$13.00
$19.00
Analyst Ratings
9Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 23, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Feb 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 20, 2026 | BTIG | REITERATE | Buy → Buy |
| Jan 29, 2026 | BTIG | REITERATE | Buy → Buy |
| Jan 21, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▼ -37.6% | $-0.06 — $0.00 | 54% YoY | 7 |
| Next Q | $0.04 ▼ -16.8% | $0.01 — $0.08 | 0% YoY | 7 |
| Current FY | $-0.05 ▼ -476.9% | $-0.16 — $0.03 | 82% YoY | 7 |
| Next FY | $0.52 ▼ -1.3% | $0.31 — $0.74 | 1177% YoY | 7 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Seven ARDX insiders, including CEO and CFO, sold a combined $176K in shares on May 21, 2026, all at the same price of $6
May 22, 2026
NEUTRAL
CLUSTER
3/10
Four C-suite insiders at Ardelyx sold $141K in open-market sales on the same day (May 21, 2026), including the CEO dispo
May 22, 2026
NEUTRAL
Press
3/10
Ardelyx announced that data on the long-term effects of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarke
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $126.8M | — |
| STATE STREET CORP | $81.5M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $62.1M | — |
| JANUS HENDERSON GROUP PLC | $50.1M | TRIM |
| NOMURA ASSET MANAGEMENT INTERNATIONAL | $48.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Kelliher Mike | SELL | $18.2K |
| May 21, 2026 | RAAB MICHAEL | SELL | $93.6K |
| May 21, 2026 | Williams Laura | SELL | $9.4K |
| May 21, 2026 | Foster Eric | SELL | $19.8K |
| May 21, 2026 | Brady James | SELL | $11.6K |
50 institutional holders with $678.0M total value (113,381,553 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 20 institutions added/increased vs 9 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 21,164,132 | $126.8M | 18.7% | — |
| 2 | STATE STREET CORP | 13,604,307 | $81.5M | 12.0% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 10,365,512 | $62.1M | 9.2% | — |
| 4 | JANUS HENDERSON GROUP PLC | 8,371,234 | $50.1M | 7.4% | TRIM -42.3% |
| 5 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 8,169,369 | $48.9M | 7.2% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,661,693 | $39.9M | 5.9% | — |
| 7 | Nuveen, LLC | 5,234,683 | $31.4M | 4.6% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 4,274,043 | $25.6M | 3.8% | — |
| 9 | CITADEL ADVISORS LLC | 3,464,774 | $20.8M | 3.1% | — |
| 10 | GOLDMAN SACHS GROUP INC | 3,216,210 | $19.3M | 2.8% | — |
| 11 | Point72 Asset Management, L.P. | 2,984,261 | $17.9M | 2.6% | DOUBLED +211.3% |
| 12 | BANK OF AMERICA CORP /DE/ | 2,336,994 | $14.0M | 2.1% | — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,114,098 | $12.7M | 1.9% | — |
| 14 | Freestone Grove Partners LP | 1,879,783 | $11.3M | 1.7% | DOUBLED +168.9% |
| 15 | Rubric Capital Management LP | 1,860,896 | $11.1M | 1.6% | NEW |
| 16 | MORGAN STANLEY | 1,708,973 | $10.2M | 1.5% | TRIM -27.5% |
| 17 | JONES FINANCIAL COMPANIES LLLP | 1,858,891 | $10.2M | 1.5% | — |
| 18 | VANGUARD FIDUCIARY TRUST CO | 1,678,111 | $10.1M | 1.5% | — |
| 19 | MARSHALL WACE, LLP | 1,600,857 | $9.6M | 1.4% | TRIM -69.1% |
| 20 | FIRST TRUST ADVISORS LP | 1,498,798 | $9.0M | 1.3% | ADD +44.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | TRIM | 14,514,692 | 8,371,234 | -42.3% | $50.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 958,690 | 2,984,261 | +211.3% | $17.9M | 2026-Q1 |
| Freestone Grove Partners LP | DOUBLED | 699,133 | 1,879,783 | +168.9% | $11.3M | 2026-Q1 |
| Rubric Capital Management LP | NEW | — | 1,860,896 | — | $11.1M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 2,358,806 | 1,708,973 | -27.5% | $10.2M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 5,188,639 | 1,600,857 | -69.1% | $9.6M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 1,036,492 | 1,498,798 | +44.6% | $9.0M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,794,793 | 1,272,441 | -29.1% | $7.6M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 327,159 | 804,734 | +146.0% | $4.8M | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 500,195 | 708,589 | +41.7% | $4.2M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 17,222 | 200,221 | +1062.6% | $1.2M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | TRIM | 283,892 | 165,498 | -41.7% | $991.3K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 98,424 | 134,413 | +36.6% | $805.1K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 677,436 | 126,306 | -81.4% | $756.6K | 2026-Q1 |
| CWM, LLC | ADD | 92,449 | 117,430 | +27.0% | $703.4K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 388,840 | 112,390 | -71.1% | $673.2K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 42,860 | 97,865 | +128.3% | $586.2K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 69,447 | 91,558 | +31.8% | $543.9K | 2026-Q1 |
| Mariner, LLC | ADD | 35,442 | 70,498 | +98.9% | $422.1K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 6 | 57,430 | +957066.7% | $344.0K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 27,116 | 56,286 | +107.6% | $337.2K | 2026-Q1 |
| STRS OHIO | DOUBLED | 27,500 | 55,300 | +101.1% | $331.2K | 2026-Q1 |
| Pictet Asset Management Holding SA | ADD | 32,479 | 40,610 | +25.0% | $243.3K | 2026-Q1 |
| Swiss Life Asset Management Ltd | ADD | 11,579 | 14,975 | +29.3% | $89.7K | 2026-Q1 |
| Allworth Financial LP | ADD | 2,815 | 5,240 | +86.1% | $31.4K | 2026-Q1 |
9 unique insiders with 24 transactions. Net insider value: $538.3K ($1.9M bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Kelliher Mike | Chief Business Officer | SELL | 2,900 | $6.27 | $18.2K |
| May 21, 2026 | RAAB MICHAEL | President & CEO | SELL | 14,933 | $6.27 | $93.6K |
| May 21, 2026 | Williams Laura A | Chief Patient Officer | SELL | 1,503 | $6.27 | $9.4K |
| May 21, 2026 | Foster Eric Duane | Chief Commercial Officer | SELL | 3,166 | $6.27 | $19.8K |
| May 21, 2026 | Brady James Parker | Chief Human Resources Officer | SELL | 1,846 | $6.27 | $11.6K |
| May 21, 2026 | Bishop John E | See Remarks | SELL | 2,306 | $6.27 | $14.5K |
| May 21, 2026 | Reilly Joseph James | See Remarks | SELL | 2,683 | $6.27 | $16.8K |
| May 21, 2026 | Hohenleitner Susan | Chief Financial Officer | SELL | 1,455 | $6.27 | $9.1K |
| May 15, 2026 | RAAB MICHAEL | President & CEO | SELL | 41,666 | $6.28 | $261.6K |
| May 15, 2026 | RAAB MICHAEL | President & CEO | EXERCISE | 20,833 | $0.9900 | $20.6K |
| Apr 15, 2026 | RAAB MICHAEL | President & CEO | EXERCISE | 20,834 | $0.9900 | $20.6K |
| Apr 15, 2026 | RAAB MICHAEL | President & CEO | SELL | 41,668 | $6.29 | $262.0K |
| Mar 16, 2026 | RAAB MICHAEL | President & CEO | EXERCISE | 20,833 | $0.9900 | $20.6K |
| Mar 16, 2026 | RAAB MICHAEL | President & CEO | SELL | 41,666 | $5.84 | $243.3K |
| Feb 24, 2026 | RAAB MICHAEL | President & CEO | EXERCISE | 20,833 | $0.9900 | $20.6K |
| Feb 20, 2026 | MOTT DAVID M | Director | BUY | 333,333 | $5.84 | $1.9M |
| Feb 20, 2026 | Bishop John E | See Remarks | SELL | 2,792 | $5.87 | $16.4K |
| Feb 20, 2026 | Reilly Joseph James | See Remarks | SELL | 4,387 | $5.87 | $25.7K |
| Feb 20, 2026 | Williams Laura A | See Remarks | SELL | 7,192 | $5.87 | $42.2K |
| Feb 20, 2026 | Hohenleitner Susan | Chief Financial Officer | SELL | 1,786 | $5.87 | $10.5K |
| Feb 20, 2026 | Brady James Parker | Chief Human Resources Officer | SELL | 2,234 | $5.87 | $13.1K |
| Feb 20, 2026 | RAAB MICHAEL | President & CEO | SELL | 40,401 | $5.87 | $237.0K |
| Feb 20, 2026 | Foster Eric Duane | Chief Commercial Officer | SELL | 9,176 | $5.87 | $53.8K |
| Feb 20, 2026 | Kelliher Mike | See Remarks | SELL | 8,434 | $5.87 | $49.5K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 2.5/10.
NEUTRAL
CLUSTER
2/10
Seven ARDX insiders, including CEO and CFO, sold a combined $176K in shares on May 21, 2026, all at
May 22, 2026
NEUTRAL
CLUSTER
3/10
Four C-suite insiders at Ardelyx sold $141K in open-market sales on the same day (May 21, 2026), inc
May 22, 2026
NEUTRAL
144
2/10
Officer John E. Bishop filed a Form 144 to sell 3,700 shares of Ardelyx common stock (~$23,000) as a
May 19, 2026
NEUTRAL
PRESS-RELEASE
3/10
Ardelyx issued a press release announcing an upcoming earnings call for Q1 2026, but did not report
Apr 16, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 94% buy across 17 analysts — 9 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$16.33 mean target (Feb 2026)
$13.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $5.69 |
| Target Low | $13.00 |
| Target Mean | $16.33 |
| Target Median | $16.00 |
| Target High | $19.00 |
| # Analysts | 9 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.06 | $0.00 | 54.1% | -37.6% | 0↑ 4↓ | $0.1B | 31.3% | 7 |
| Next Q 2026-09-30 |
$0.04 | $0.01 | $0.08 | 0.0% | -16.8% | 2↑ 2↓ | $0.2B | 37.0% | 7 |
| Current FY 2026-12-31 |
$-0.05 | $-0.16 | $0.03 | 81.6% | -476.9% | — | $0.5B | 33.9% | 7 |
| Next FY 2027-12-31 |
$0.52 | $0.31 | $0.74 | 1176.9% | -1.3% | 3↑ 0↓ | $0.7B | 35.2% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.037 | |
| 7d ago | $-0.020 | -0.017 |
| 30d ago | $-0.027 | -0.010 |
| 60d ago | $-0.026 | -0.011 |
| 90d ago | $0.036 | -0.073 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 23, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Feb 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 29, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 21, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Piper Sandler | UPGRADE | Neutral | Overweight |
| Jan 9, 2026 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 10 | 7 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 10 | 7 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 10 | 7 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 9 | 6 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: ARDX — 55.5% short (0.6M / 1.0M)
Short: 570,533 | Exempt: 1,846 | TRF Vol: 1,027,365 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
other
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
<p>WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical c
May 15, 2026
short_volume
Short Volume: ARDX — 59.8% short (0.7M / 1.2M)
Short: 690,114 | Exempt: 2,033 | TRF Vol: 1,153,909 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
fda
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
<p>WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the develo
Apr 30, 2026
earnings
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year</em></p>
Apr 30, 2026
earnings_calendar
ARDX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
fda
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers <pre>Presentation evaluates the long-ter
Apr 23, 2026
other
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
<p>WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the deve
Apr 16, 2026
earnings
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Conference call scheduled for 4:30 p.m. Eastern Time <pre>Conference call scheduled for 4:30 p.m. Eastern Time</pre>
Apr 1, 2026
other
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
<p>WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and comme
Mar 26, 2026
short_volume
Short Volume: ARDX — 55.1% short (0.7M / 1.2M)
Short: 677,728 | Exempt: 3,311 | TRF Vol: 1,229,888 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_interest
FTD: ARDX — 711,463 shares ($3.8M) failed to deliver
Settlement: 20260325, Price: $5.35, FTD Value: $3,806,327.05, ARDELYX INC COM STK (DE)
Mar 9, 2026
fda
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort,